HomeAI · summaries
Storia in 2 fonti
Evommune's lead drug flunks its second I&I trial this summer
Evommune's EVO756 flops in Phase 2b eczema trial, its second mid-stage miss this summer; MRGPRX2 drug's migraine study continues.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Evommune's lead drug flunks its second I&I trial this summer
Evommune's EVO756 flops in Phase 2b eczema trial, its second mid-stage miss this summer; MRGPRX2 drug's migraine study continues.
- ·
benzinga.com
Evommune Halts Atopic Dermatitis Program Following Trial Failure - Evommune (NYSE:EVMN)
Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.